Biomaterials Research (생체재료학회지)

Korean Society for Biomaterials (한국생체재료학회)
권호 표지

Development of Gemcitabine-incorporated Polyurethane Films Intended for Local Delivery of Anti-cancer Drug

항암제의 국소 전달을 위한 젬시타빈 함유 폴리우레탄 피막의 개발

  • Park, Sangsoo (Department of Biomedical Engineering, Eulji University)
  • Published : 2012.06.01
⟨ Previous Next ⟩

Abstract

Gemcitabine, a cytidine analogues, is one of the most potent chemotherapeutic agent, but its clinical use in chemotherapy is limited to breast cancer, ovarian cancer, non-small cell lung cancer, and pancreatic cancer due to its very short half-life. Various methods have been developed to increase its in vivo bioavailability, including incorporation into liposomes and polymeric nanoparticles, and developing prodrugs that slowly convert to gemcitabine inside the body. We incorporated gemcitabine into a polyurethane film, and studied its in vitro release behavior with an aim to apply the gemcitabine-incorporated polyurethane film for stent covering that could help control the proliferation of malignant tumor around the stent in the gastrointestinal tract.

Keywords

References

  1. H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano, M. C. Cripps, R. K. Portenoy, A. M. Storniolo, P. Tarassoff, R. Nelson, F. A. Dorr, C. D. Stephens and D. D. Von Hoff, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial," J. Clin. Oncol., 15, 2403- 2413 (1997).
  2. J. W. Kim, "Recent treatment of pancreatic cancer," Korean J. Med., 77(6), 695-702 (2009).
  3. M. Blackstein, C. L. Vogel, R. Ambinder, J. Cowan, J. Iglesias and A. Melemed, "Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial," Oncology, 62, 2-8 (2002).
  4. M. Tempero, W. Plunkett, V. Ruiz van Haperen, J. Hainsworth, H. Hochster, R. Lenzi, J. Abbruzzese, "Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma," J. Clin. Oncol., 21, 3402-3408 (2003).
  5. W. Plunkett, P. Huang and V. Gandhi, "Preclinical characteristics of gemcitabine," Anticancer Drugs, 6(6), 7-13 (1995).
  6. J. L. Abbruzzese, R. Grunewald, E. A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Sattlee and M. N. Raber, "A phase I clinical, plasma, and cellular pharmacology study of gemcitabine," J. Clin. Oncol., 9, 491-498 (1991).
  7. J. M. Reid, W. Qu, S. L. Safgren, M. M. Ames, M. D. Krailo, N. L. Seibel, J. Kuttesch and J. Holcenberg, "Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors," J. Clin. Oncol., 22, 2445-2451 (2004).
  8. R. Moog, A. M. Burger, M. Brandl, J. Schuler, R. Schubert, C. Unger, H. H. Fiebiq and U. Massing, "Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels," Cancer Chemother. Pharmacol., 49, 356-366 (2002).
  9. G. K. Abou-Alfa, R. Letourneau, G. Harker, M. Modiano, H. Hurwitz, N. S. Tchekmedyian, K. Feit, J. Ackerman, R. L. De Jager, S. G. Eckhardt and E. M. O'Reilly, "Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer," J. Clin. Oncol., 24, 4441-4447 (2006).
  10. B. F. El-Rayes, M. M. Zalupski, A. F. Shields, U. Vaishampayan, L. K. Heilbrun, V. Jain, J. Day and P. A. Philip, "Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer," J. Clin. Oncol., 21, 2920-2925 (2003).
  11. R. G. Maki, J. K. Wathen, S. R. Patel, D. A. Priebat, S. H. Okuno, B. Samuels, M. Fanucchi, D, C, Harmon, S. M. Schuetze, D. Reinke, P. F. Thall, R. S. Benjamin, L. H. Baker and M. L. Hensley, "Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]," J. Clin. Oncol., 25, 2755-2763 (2007).
  12. M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski and W. Parulekar, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group," J. Clin. Oncol., 25, 1960-1966 (2007).
  13. C. Sederholm, G. Hillerdal, K. Lamberg, K. Kolbeck, M. Dufmats, R. Westberg and S. R. Gawande, "Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the swedish lung cancer study group," J. Clin. Oncol., 23, 8380-8388 (2005).
  14. Eli Lylli, "Gemcitabine hydrochloride for injection," Material safety data sheet, (2005).
  15. J. R. Mackey, R. S. Mani, M. Selner, D. Mowles, J. D. Young, J. A. Belt, C. R. Crawford and C. E. Cass, "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines," Cancer Res., 58, 4349-4357 (1998).
  16. M. Pastor-Anglada, M, Molina-Arcas, F. J. Casado, B. Bellosillo, D. Colomer and J. Gil, "Nucleoside transporters in chronic lymphocytic leukaemia," Leukemia, 18, 385-393 (2004).
  17. V. Heinemann, L. W. Hertel, G. B. Grindey and W. Plunkett, "Comparison of the cellular pharmacokinetics and toxicity of 2',2'- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine," Cancer Res., 48, 4024-4031 (1988).
  18. M. G. Calvagno, C. Celia, D. Paolino, D. Cosco, M. Iannone, F. Castelli, P. Doldo and M. Frest, "Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabineloaded liposomes," Curr. Drug. Deliv., 4, 89-101 (2007).
  19. M. L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti and L. Cattel, "Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs," J. Control. Release, 100, 331-346 (2004).
  20. J. S. Falconer, J. A. Ross, K. C. Fearon, R. A. Hawkins, M. G. O'Riordain and D. C. Carter, "Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines," Br. J. Cancer, 69, 826-832 (1994).
  21. D. Ravichandran, A. Cooper and C. D. Johnson, "Effect of lithium gamma-linolenate on the growth of experimental human pancreatic carcinoma," Br. J. Surg., 85, 1201-1205 (1998).
  22. M. M. Guffy, J. A. North and C. P. Burns, "Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells," Cancer Res., 44, 1863-1866 (1984).
  23. D. P. Rose, J. M. Connolly, J. Rayburn and M. Coleman, "Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice," J. Natl. Cancer Inst., 87, 587-592 (1995).
  24. J. G. Zijlstra, E. G. de Vries, F. A. Muskiet, I. A. Martini, H. Timmer- Bosscha and N. H. Mulder, "Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines," Int. J. Cancer, 40, 850-856 (1987).
  25. K. L. Black, K. Ikezaki and A. W. Toga, "Imaging of brain tumors using peripheral benzodiazepine receptor ligands," J. Neurosurg., 71, 113-118 (1989).
  26. K. L. Black, K. Ikezaki, E. Santori, D. P. Becker and H. V. Vinters, "Specific high-affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man," Cancer, 65, 93-97 (1990).
  27. A. A. El-Mabhouha, C. A. Angelovb, R. Cavellb, J. R. Mercer, "A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer," Nucl. Med. Biol., 33(6), 715-722 (2006).
  28. J. Yang, S. B. Park, H. G. Yoon, Y. M. Huh and S. Haam, "Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier," Int. J. Pharm., 324, 185-190 (2006).
  29. J. Yang, H. Lee, W. Hyung, S. B. Park and S. Haam, "Magnetic PECA nanoparticles as drug carriers for targeted delivery: synthesis and release characteristics," J. Microencapsul., 23, 203-212 (2006).
  30. L. S. Huang, C. X. Wang, Z. L. Chen, J. Wan, X. Q. Yan and G. Duan, "Preparation of gemcitabine polybutylcyanoacrylate nanoparticles," Nan Fang Yi Ke Da Xue Xue Bao, 27, 1653-1656 (2007).
  31. B. Stella, S. Arpicco, F. Rocco, V. Marsaud, J. M. Renoir, L. Cattel and P. Couvreur, "Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules," Int. J. Pharm., 344, 71-77 (2007).
  32. J. L. Arias, L. H. Reddy and P. Couvreur, "Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine," J. Drug Target, 17, 586-598 (2009)
  33. L. H. Reddy and P. Couvreur, "Novel approaches to deliver gemcitabine to cancers," Curr. Pharm. Res., 14, 1124-1137 (2008).
  34. J. Gunn and D. Cumberland, "Stent coatings and local drug delivery: State of the art," Eur Heart J., 20, 1693-1700 (1999).
  35. J. L. Arias, L. H. Reddy and P. Couvreur, "Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system" - Biomacromolecules, 12, 97-104 (2011).
  36. M. S. Shin and S. Park. "Gemcitabine Release Behavior of Polyurethane Matrixes Designed for Local Anti-Cancer Drug Delivery via Stent," J. Drug Del. Sci. Technol. in print (2012).
  37. D. S. Risley, W. Q. Yang and J. A. Peterson, "Analysis of mannitol in pharmaceutical formulations using hydrophilic interaction liquid chromatography with evaporative light-scattering detection," J. Sep. Sci., 29, 256-264 (2006).
  38. Y. J. Yi, D. Hatziavramidis, A. S. Myerson, M. Waldo, V. G. Beylin and J. Mustakis, "Development of a small-scale automated solubility measurement apparatus," Ind. & Eng. Chem. Res., 44, 5427-5433 (2005).
  39. M. J. Chung, H Kim., K. S. Kim, S. Park, J. B. Chung and S. W. Park, "Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model," J Gastroenterol Hepatol. 27(2), 261-7 (2012).
  40. K. B. Freeman, S. Anliker, M. Hamilton, D. Osborne, P. H. Dhahir, R. Nelson and S. R. Allerheiligen, "Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection," J. Chromatogr. B. Biomed. Appl., 665(1), 171-181 (1995).
  41. A. P. Venook, M. J. Egorin, G. L. Rosner, D. Hollis, S. Mani, M. Hawkins, J. Byrd, R. Hohl, D. Budman, N. J. Meropol and M. J. Ratain, "Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565," J. Clin. Oncol., 18(14), 2780-2787 (2000).
  42. A. Patnaik, E. K. Rowinsky, B. K. Tammara, M. Hidalgo, R. L. Drengler, A. M. Garner, L. L. Siu, L. A. Hammond, S. A. Felton, S. Mallikaarjun, D. D. Von Hoff and S. G. Eckhardt, "Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer," J. Clin. Oncol., 18(23), 3974-3985 (2000).
  43. B. Keith, Y. Xu and J. L. Grem, Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography," J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 785(1), 65-72 (2003).
  44. B. Yilmaz, Y. Y. Kadioglu and Y. Aksoy, "Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography," J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 791(1-2), 103-109 (2003).
  45. M. N. Kirstein, I. Hassan, D. E. Guire, D. R. Weller, J. W. Dagit, J. E. Fisher and R. P. Remmel, "High-performance liquid vhromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media," J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 835(1-2), 136-142 (2006).
  46. R. Losa, M. I. Sierra, M. O. Gion, E. Esteban and J. M. Buesa, "Simultaneous determination of gemcitabine Di-and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection," J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 840(1), 44-49 (2006).